Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
7021 | 1415 | 33.0 | 73% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
7 | 4 | INFECTIOUS DISEASES//MICROBIOLOGY//VIROLOGY | 1353914 |
29 | 3 | HIV//VIROLOGY//HIV 1 | 108954 |
773 | 2 | EFAVIRENZ//NEVIRAPINE//RALTEGRAVIR | 12242 |
7021 | 1 | RALTEGRAVIR//DOLUTEGRAVIR//ETRAVIRINE | 1415 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | RALTEGRAVIR | authKW | 2812867 | 14% | 65% | 202 |
2 | DOLUTEGRAVIR | authKW | 1679895 | 6% | 91% | 86 |
3 | ETRAVIRINE | authKW | 1275723 | 6% | 66% | 90 |
4 | INTEGRASE INHIBITOR | authKW | 1248588 | 9% | 48% | 121 |
5 | DARUNAVIR | authKW | 1061935 | 7% | 47% | 105 |
6 | ELVITEGRAVIR | authKW | 910454 | 4% | 74% | 57 |
7 | RILPIVIRINE | authKW | 718651 | 4% | 57% | 58 |
8 | COBICISTAT | authKW | 505754 | 2% | 76% | 31 |
9 | INTEGRASE STRAND TRANSFER INHIBITORS | authKW | 271125 | 1% | 74% | 17 |
10 | TREATMENT EXPERIENCED | authKW | 259406 | 2% | 52% | 23 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Infectious Diseases | 52773 | 57% | 0% | 808 |
2 | Virology | 14080 | 24% | 0% | 342 |
3 | Pharmacology & Pharmacy | 8314 | 45% | 0% | 637 |
4 | Immunology | 4629 | 28% | 0% | 400 |
5 | Microbiology | 3776 | 22% | 0% | 317 |
6 | Medicine, General & Internal | 109 | 6% | 0% | 82 |
7 | Toxicology | 69 | 3% | 0% | 41 |
8 | Medical Laboratory Technology | 13 | 1% | 0% | 11 |
9 | Biochemical Research Methods | 8 | 2% | 0% | 26 |
10 | Health Care Sciences & Services | 2 | 1% | 0% | 10 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | HIV UNIT | 92241 | 3% | 11% | 40 |
2 | HP VIROLU943 | 77062 | 0% | 71% | 5 |
3 | NORTHSTAR MED | 64734 | 0% | 100% | 3 |
4 | LLUITA SIDA FDN | 57275 | 1% | 15% | 18 |
5 | HOSP JUAN FERNANDEZ | 48549 | 0% | 75% | 3 |
6 | ARNAS AZIENDA OSPED RILIEVO NAZL ALTA SPECIALIZ | 43156 | 0% | 100% | 2 |
7 | CLINICIZZATA MALATTIE INFETT | 43156 | 0% | 100% | 2 |
8 | COREVIH PAYS DE LA LOIRE | 43156 | 0% | 100% | 2 |
9 | EMEAC | 43156 | 0% | 100% | 2 |
10 | GEN HOSP 2 | 43156 | 0% | 100% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | HIV CLINICAL TRIALS | 77695 | 3% | 8% | 43 |
2 | ANTIVIRAL THERAPY | 51670 | 5% | 4% | 67 |
3 | AIDS REVIEWS | 44826 | 2% | 9% | 24 |
4 | HIV MEDICINE | 41763 | 3% | 4% | 46 |
5 | JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 33509 | 6% | 2% | 81 |
6 | AIDS | 27572 | 7% | 1% | 105 |
7 | JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 23600 | 8% | 1% | 117 |
8 | AIDS RESEARCH AND HUMAN RETROVIRUSES | 8480 | 3% | 1% | 46 |
9 | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 7796 | 7% | 0% | 93 |
10 | AIDS RESEARCH AND THERAPY | 7345 | 1% | 3% | 10 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | RALTEGRAVIR | 2812867 | 14% | 65% | 202 | Search RALTEGRAVIR | Search RALTEGRAVIR |
2 | DOLUTEGRAVIR | 1679895 | 6% | 91% | 86 | Search DOLUTEGRAVIR | Search DOLUTEGRAVIR |
3 | ETRAVIRINE | 1275723 | 6% | 66% | 90 | Search ETRAVIRINE | Search ETRAVIRINE |
4 | INTEGRASE INHIBITOR | 1248588 | 9% | 48% | 121 | Search INTEGRASE+INHIBITOR | Search INTEGRASE+INHIBITOR |
5 | DARUNAVIR | 1061935 | 7% | 47% | 105 | Search DARUNAVIR | Search DARUNAVIR |
6 | ELVITEGRAVIR | 910454 | 4% | 74% | 57 | Search ELVITEGRAVIR | Search ELVITEGRAVIR |
7 | RILPIVIRINE | 718651 | 4% | 57% | 58 | Search RILPIVIRINE | Search RILPIVIRINE |
8 | COBICISTAT | 505754 | 2% | 76% | 31 | Search COBICISTAT | Search COBICISTAT |
9 | INTEGRASE STRAND TRANSFER INHIBITORS | 271125 | 1% | 74% | 17 | Search INTEGRASE+STRAND+TRANSFER+INHIBITORS | Search INTEGRASE+STRAND+TRANSFER+INHIBITORS |
10 | TREATMENT EXPERIENCED | 259406 | 2% | 52% | 23 | Search TREATMENT+EXPERIENCED | Search TREATMENT+EXPERIENCED |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | PARK, TE , MOHAMED, A , KALABALIK, J , SHARMA, R , (2015) REVIEW OF INTEGRASE STRAND TRANSFER INHIBITORS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION.EXPERT REVIEW OF ANTI-INFECTIVE THERAPY. VOL. 13. ISSUE 10. P. 1195 -1212 | 59 | 84% | 3 |
2 | KANDEL, CE , WALMSLEY, SL , (2015) DOLUTEGRAVIR - A REVIEW OF THE PHARMACOLOGY, EFFICACY, AND SAFETY IN THE TREATMENT OF HIV.DRUG DESIGN DEVELOPMENT AND THERAPY. VOL. 9. ISSUE . P. 3547 -3555 | 53 | 78% | 6 |
3 | ANTINORI, A , MARCOTULLIO, S , ANDREONI, M , CHIRIANNI, A , MONFORTE, AD , DI BIAGIO, A , GALLI, M , MAZZOTTA, F , MUSSINI, C , PUOTI, M , ET AL (2016) ITALIAN GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS AND THE DIAGNOSTIC-CLINICAL MANAGEMENT OF HIV-1 INFECTED PERSONS. UPDATE 2015.NEW MICROBIOLOGICA. VOL. 39. ISSUE 2. P. 93 -109 | 69 | 59% | 1 |
4 | TAHA, H , DAS, A , DAS, S , (2015) CLINICAL EFFECTIVENESS OF DOLUTEGRAVIR IN THE TREATMENT OF HIV/AIDS.INFECTION AND DRUG RESISTANCE. VOL. 8. ISSUE . P. 339 -352 | 49 | 83% | 4 |
5 | LLIBRE, JM , PULIDO, F , GARCIA, F , DELTORO, MG , BLANCO, JL , DELGADO, R , (2015) GENETIC BARRIER TO RESISTANCE FOR DOLUTEGRAVIR.AIDS REVIEWS. VOL. 17. ISSUE 1. P. 56 -64 | 40 | 91% | 11 |
6 | MESPLEDE, T , QUASHIE, PK , ZANICHELLI, V , WAINBERG, MA , (2014) INTEGRASE STRAND TRANSFER INHIBITORS IN THE MANAGEMENT OF HIV-POSITIVE INDIVIDUALS.ANNALS OF MEDICINE. VOL. 46. ISSUE 3. P. 123-129 | 44 | 92% | 8 |
7 | DEHORITY, W , ABADI, J , WIZNIA, A , VIANI, RM , (2015) USE OF INTEGRASE INHIBITORS IN HIV-INFECTED CHILDREN AND ADOLESCENTS.DRUGS. VOL. 75. ISSUE 13. P. 1483 -1497 | 50 | 83% | 0 |
8 | KARMON, SL , MARKOWITZ, M , (2013) NEXT-GENERATION INTEGRASE INHIBITORS WHERE TO AFTER RALTEGRAVIR?.DRUGS. VOL. 73. ISSUE 3. P. 213 -228 | 47 | 78% | 27 |
9 | LIEDTKE, MD , TOMLIN, CR , LOCKHART, SM , MILLER, MM , RATHBUN, RC , (2014) LONG-TERM EFFICACY AND SAFETY OF RALTEGRAVIR IN THE MANAGEMENT OF HIV INFECTION.INFECTION AND DRUG RESISTANCE. VOL. 7. ISSUE . P. 73 -84 | 43 | 91% | 4 |
10 | MESPLEDE, T , WAINBERG, MA , (2015) RESISTANCE AGAINST INTEGRASE STRAND TRANSFER INHIBITORS AND RELEVANCE TO HIV PERSISTENCE.VIRUSES-BASEL. VOL. 7. ISSUE 7. P. 3703 -3718 | 44 | 79% | 8 |
Classes with closest relation at Level 1 |